Multiple effects of 2,3-butanedione monoxime.

2,3-Butanedione monoxime, also known as diacetyl monoxime, is a nucleophilic agent which dephosphorylates acetylcholinesterase poisoned with organophosphates. This "chemical phosphatase" activity stimulated studies of the effect of 2,3-butanedione monoxime on phosphorylation-dependent cellular processes. As a result of these studies, we know that the drug affects a number of mechanisms including muscle contraction, ionic current flow and synaptic transmission. Furthermore, it may be used as a component of cardioplegic solutions since it protects cardiac tissue exposed to certain ischaemic conditions. While this MiniReview reveals the diversity of its cellular actions, there continues to be unresolved questions regarding its molecular mechanism.

[1]  S. Ikeda,et al.  2,3-Butanedione monoxime blockade of Ca2+ currents in adult rat sympathetic neurons does not involve ‘chemical phosphatase’ activity , 1993, Neuroscience Letters.

[2]  W. Nayler,et al.  Contracture and the Calcium Paradox in the Rat Heart , 1987, Circulation research.

[3]  R. Paul,et al.  Effects of 2,3‐butanedione monoxime on whole‐cell Ca2+ channel currents in single cells of the guinea‐pig taenia caeci. , 1991, The Journal of physiology.

[4]  J H Southard,et al.  Principles of solid-organ preservation by cold storage. , 1988, Transplantation.

[5]  J. Southard,et al.  Improved myocardial ischemic tolerance by contractile inhibition with 2,3-butanedione monoxime. , 1992, The Annals of thoracic surgery.

[6]  N. Sperelakis,et al.  Effects of diacetyl monoxime (DAM) on slow and fast action potentials of young and old embryonic chick hearts and rabbit hearts. , 1985, European journal of pharmacology.

[7]  A. L. Green,et al.  The reactivation by oximes and hydroxamic acids of cholinesterase inhibited by organo-phosphorus compounds. , 1955, British journal of pharmacology and chemotherapy.

[8]  W. Nayler,et al.  Dissociation of hypoxia-induced calcium gain and rise in resting tension in isolated rat hearts. , 1988, The American journal of physiology.

[9]  J. Wiggins,et al.  Oximes: 'enzymatic' slow channel antagonists in canine cardiac purkinje fibers? , 1981, European journal of pharmacology.

[10]  J. Maylie,et al.  Multiple actions of 2,3‐butanedione monoxime on contractile activation in frog twitch fibres. , 1991, The Journal of physiology.

[11]  W. Nayler,et al.  The stunned myocardium: effect of electrical and mechanical arrest and osmolarity. , 1988, The American journal of physiology.

[12]  M. Böhm,et al.  Force-frequency relation in human heart failure. , 1992, Circulation.

[13]  B. Ginsburg,et al.  A powerful reactivator of alkylphosphate-inhibited acetylcholinesterase. , 1955, Biochimica et biophysica acta.

[14]  N. Sperelakis,et al.  Effects of diacetyl monoxime on cardiac excitation-contraction coupling. , 1985, The Journal of pharmacology and experimental therapeutics.

[15]  Y. Kasuya,et al.  Effects of oximes, diacetylmonoxime, pyridine-2-aldoxime, and pyridine-2-aldoxime methochloride, on the electrical and mechanical activities of guinea pig cardiac ventricular muscles. , 1985, Journal of pharmacobio-dynamics.

[16]  Jager Bv,et al.  Toxicity of diacetyl monoxime and of pyridine-2-aldoxime methiodide in man. , 1958 .

[17]  B. Askew,et al.  Oximes and hydroxamic acids as antidotes in anticholinesterase poisoning. , 1956, British journal of pharmacology and chemotherapy.

[18]  D. Burkhoff,et al.  Comparison between the effects of 2–3 dutanedione monoxime (BDM) and calcium chloride on myocardial oxygen consumption , 1992 .

[19]  A. L. Green,et al.  756. The reaction of oximes with isopropyl methylphosphono-fluoridate (Sarin) , 1956 .

[20]  M. Epstein,et al.  Studies on a group of oximes as therapeutic compounds in sarin poisoning. , 1957, The Journal of pharmacology and experimental therapeutics.

[21]  P. Pahapill,et al.  Dual action of 2,3-butanedione monoxime (BDM) on K+ current in human T lymphocytes. , 1992, The Journal of pharmacology and experimental therapeutics.

[22]  H. Higuchi,et al.  Butanedione monoxime suppresses contraction and ATPase activity of rabbit skeletal muscle. , 1989, Journal of biochemistry.

[23]  C. Herrmann,et al.  Effect of 2,3-butanedione monoxime on myosin and myofibrillar ATPases. An example of an uncompetitive inhibitor. , 1992, Biochemistry.

[24]  M. W. Fryer,et al.  Effects of 2,3‐butanedione monoxime on the contractile activation properties of fast‐ and slow‐twitch rat muscle fibres. , 1988, The Journal of physiology.

[25]  R. J. Johns,et al.  Treatment of anticholinesterase intoxication with oximes; use in normal subjects and in patients with myasthenia gravis. , 1958, Journal of the American Medical Association.

[26]  F. Fernández‐Avilés,et al.  Selective Inhibition of the Contractile Apparatus: A New Approach to Modification of Infarct Size, Infarct Composition, and Infarct Geometry During Coronary Artery Occlusion and Reperfusion , 1992, Circulation.

[27]  A. Coulombe,et al.  Effect of 2,3-butanedione 2-monoxime on slow inward and transient outward currents in rat ventricular myocytes. , 1990, Journal of molecular and cellular cardiology.

[28]  Nayler Wg,et al.  Contractile activity and reperfusion-induced calcium gain after ischemia in the isolated rat heart. , 1988 .

[29]  N. Alpert,et al.  Protection of Human Left Ventricular Myocardium From Cutting Injury With 2,3 -Butanedione Monoxime , 1989, Circulation research.

[30]  W. Nayler,et al.  The role of calcium in the toxic effects of tert-butyl hydroperoxide on adult rat cardiac myocytes. , 1991, Journal of molecular and cellular cardiology.

[31]  J. McArdle,et al.  Effects of butanedione monoxime on neuromuscular transmission , 1990, British journal of pharmacology.

[32]  Z. Bosnjak,et al.  Opposing effects of diacetyl monoxime on contractility and calcium transients in isolated myocardium. , 1991, The American journal of physiology.

[33]  B. Jager,et al.  Studies on distribution and disappearance of pyridine-2-aldoxime methiodide (PAM) and of diacetyl monoxime (DAM) in man and in experimental animals. , 1958, Bulletin of the Johns Hopkins Hospital.

[34]  B. Siegmund,et al.  Prevention of the oxygen paradox in hypoxic-reoxygenated hearts. , 1991, The American journal of physiology.

[35]  N. Alpert,et al.  Tension‐independent heat in rabbit papillary muscle. , 1989, The Journal of physiology.

[36]  R. Singleton.  Bioorganic chemistry of phosphorus. , 1973, Journal of Chemical Education.

[37]  R. J. Johns,et al.  Treatment of anticholinesterase intoxication with oximes , 1958, Neurology.

[38]  R. Hajjar,et al.  Contractile deactivation and uncoupling of crossbridges. Effects of 2,3-butanedione monoxime on mammalian myocardium. , 1991, Circulation research.

[39]  J. Wiggins,et al.  Inotropic actions of diacetyl monoxime in cat ventricular muscle. , 1980, The Journal of pharmacology and experimental therapeutics.

[40]  B. Ransil,et al.  Cellular basis of negative inotropic effect of 2,3-butanedione monoxime in human myocardium. , 1992, The American journal of physiology.

[41]  J. Maylie,et al.  Action of 2,3‐butanedione monoxime on calcium signals in frog cut twitch fibres containing antipyrylazo III. , 1991, The Journal of physiology.

[42]  C. Ganote,et al.  Effects of 2,3-butanedione monoxime (BDM) on contracture and injury of isolated rat myocytes following metabolic inhibition and ischemia. , 1991, Journal of molecular and cellular cardiology.

[43]  Y. Saeki,et al.  Effects of length change on intracellular Ca2+ transients in ferret ventricular muscle treated with 2,3-butanedione monoxime (BDM). , 1990, The Japanese journal of physiology.

[44]  J. McArdle,et al.  Novel suppression of an L‐type calcium channel in neurones of murine dorsal root ganglia by 2,3‐butanedione monoxime. , 1992, The Journal of physiology.